Heather Douangpanya

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Jonathan D. Graves, Jennifer J. Kordich, Tzu-Hsuan Huang et al. · Cancer Cell · 2014 · 154 citations · Full text

Antitumor Activity, G Protein-coupled Receptor, Medicine +9

DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.

Adam Kashishian, Heather Douangpanya, Darcey Clark et al. · PubMed · 2003 · 92 citations

Tumor Biology, Genome Instability, Oncology +15

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Pamela M. Holland, Robert E. Miller, Jon C. Jones et al. · Cancer Biology & Therapy · 2010 · 39 citations · Full text

Breast Oncology, Chemoprevention Strategy, Pathology +20